Figure 4.

Five-year disease-specific survival rates. The disease-specific survival rates were 88.8 and 86.4% in the S-1 and AI groups, respectively, showing a similar survival curve with no significant difference in the survival rate. S-1, concurrent neoadjuvant chemoradiotherapy with S-1 and a total external irradiation dose of 30 Gy; AI, concurrent neoadjuvant chemoradiotherapy using super-selective intra-arterial infusion with cisplatin or carboplatin and a total external irradiation dose of 40 Gy.